PDF herunterladen
CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2021; 11(01): 01-07
DOI: 10.1055/s-0040-1718848
Review Article

Comorbidities in Patients with COVID-19 and Their Impact on the Severity of the Disease

Shahid Bashir
1   Neuroscience Center, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia
,
Sadaf Moneeba
2   Department of Bioinformatics and Biotechnology, International Islamic University Islamabad, Islamabad, Pakistan
,
Alaa Alghamdi
3   King Fahad University Hospital, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
,
Fouad Alghamdi
1   Neuroscience Center, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia
,
Asim Niaz
1   Neuroscience Center, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia
,
Hadeel Anan
1   Neuroscience Center, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia
,
Imdad Kaleem
4   Department of Bioinformatics and Biosciences, COMSATS University (CUI), Islamabad, Pakistan
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Infection with COVID-19 is associated with significant morbidity, especially in patients with chronic medical conditions. At least one-fifth of cases require supportive care in intensive care units, which have limited availability in most developing countries. A literature search was conducted on PubMed, Medline, Scopus, Embase, and Google Scholar to find articles published by May 7, 2020 on the role of comorbidities in patients with COVID-19 and the impact of comorbidities on the disease. This review highlighted that patients with comorbidities are more likely to experience severe disease than those with no other conditions; that is, comorbidities correlated with greater disease severity in patients with COVID-19. Proper screening of COVID-19 patients should include careful inquiries into their medical history; this will help healthcare providers identify patients who are more likely to develop serious disease or experience adverse outcomes. Better protection should also be given to patients with COVID-19 and comorbidities upon confirmation of the diagnosis. This literature review showed that the comorbidities most often associated with more severe cases of COVID-19 are hypertension, cardiovascular disease, and diabetes. Individuals with these comorbidities should adopt restrictive measures to prevent exposure to COVID-19, given their higher risk of severe disease.

Keywords

COVID-19 - morbidity - comorbidities - pandemic


Publikationsverlauf

Artikel online veröffentlicht:
16. Oktober 2020

© 2020. Nitte University (Deemed to be University). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hui DS, I. Azhar E, Madani TA. et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91: 264-266 DOI: 10.1016/j.ijid.2020.01.009.
    CrossrefPubMedGoogle Scholar
  • 2 Wu Y, Ho W, Huang Y. et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet 2020; 395 (10228) 949-950
    CrossrefPubMedGoogle Scholar
  • 3 Worldometer. Available at: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1? Accessed October 5, 2020
  • 4 Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019. MMWR Morb Mortal Wkly Rep. CDC; February 12-March 28 2020
  • 5 Coronavirus disease. 2019 (COVID-19) in the EU/EEA and the UK – eighth update. European Center for Disease Prevention and Control. 2020
    Google Scholar
  • 6 Bommer W. CDC offers guidance to patients with chronic disease 'living with uncertainty' during COVID-19. Healio Rheumatology. 2020
    Google Scholar
  • 7 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229) 1054-1062
    Google Scholar
  • 8 Yang J, Zheng Y, Gou X. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-95
    Google Scholar
  • 9 Guan W-J, Liang W-H, Zhao Y. et al. China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; 55 (05) 2000547
    CrossrefPubMedGoogle Scholar
  • 10 Peng YD, Meng K, Guan HQ. et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48 (06) 450-455
    PubMedGoogle Scholar
  • 11 Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med 2020; 8 (01) e35
    PubMedGoogle Scholar
  • 12 Fang L, Gao P, Bao H. et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med 2018; 6 (06) 421-430
    CrossrefPubMedGoogle Scholar
  • 13 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223) 497-506
    CrossrefPubMedGoogle Scholar
  • 14 Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323 (11) 1061-1069
    CrossrefPubMedGoogle Scholar
  • 15 Zhang JJ, Dong X, Cao YY. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75 (07) 1730-1741
    CrossrefPubMedGoogle Scholar
  • 16 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223) 507-513
    CrossrefPubMedGoogle Scholar
  • 17 Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41 (02) 145-151
    Google Scholar
  • 18 Guo W, Li M, Dong Y. et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020; DOI: 10.1002/dmrr.3319.
    CrossrefPubMedGoogle Scholar
  • 19 S. Hu, R. Gao, L. Liu, M. Zhu, W. Wang, Y. Wang, et al. Summary of the 2018 report on cardiovascular diseases in China Chin Circ J, 34 (2019), p. 209
  • 20 Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92 (06) 552-555
    CrossrefPubMedGoogle Scholar
  • 21 Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol 2020
  • 22 Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol 2020
  • 23 Li B, Yang J, Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109 (05) 531-538
    Google Scholar
  • 24 Mertz D, Kim TH, Johnstone J. et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013; 347: f5061
    CrossrefPubMedGoogle Scholar
  • 25 Mao R, Liang J, Shen J. et al. Chinese Society of IBD, Chinese Elite IBD Union; Chinese IBD Quality Care Evaluation Center Committee. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol 2020; 5 (05) 425-427
    CrossrefPubMedGoogle Scholar
  • 26 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21 (03) 335-337
    CrossrefPubMedGoogle Scholar
  • 27 Cheng Y, Luo R, Wang K. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97 (05) 829-838
    Google Scholar
  • 28 Chu KH, Tsang WK, Tang CS. et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 2005; 67 (02) 698-705
    CrossrefPubMedGoogle Scholar
  • 29 Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). J Clin Med 2020; 9 (03) 841
    CrossrefPubMedGoogle Scholar
  • 30 Lawrence H, Hunter A, Murray R, Lim WS, McKeever T. Cigarette smoking and the occurrence of influenza - Systematic review. J Infect 2019; 79 (05) 401-406
    CrossrefPubMedGoogle Scholar
  • 31 Han L, Ran J, Mak YW. et al. Smoking and Influenza-associated Morbidity and Mortality: A Systematic Review and Meta-analysis. Epidemiology 2019; 30 (03) 405-417
    CrossrefPubMedGoogle Scholar
  • 32 Simonnet A, Chetboun M, Poissy J. et al. LICORN and the Lille COVID-19 and Obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020; 28 (07) 1195-1199
    Google Scholar
  • 33 Bhatraju PK, Ghassemieh BJ, Nichols M. et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med 2020; 382 (21) 2012-2022
    CrossrefPubMedGoogle Scholar
  • 34 Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. BMJ 2020;369:m1966
  • 35 Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol 2020; 16 (07) 341-342
    CrossrefPubMedGoogle Scholar
  • 36 Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harb Perspect Med 2012; 2 (03) a007724
    CrossrefPubMedGoogle Scholar
  • 37 Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009; 9 (12) 737-746
    CrossrefPubMedGoogle Scholar
  • 38 Hong KW, Cheong HJ, Choi WS. et al. Clinical courses and outcomes of hospitalized adult patients with seasonal influenza in Korea, 2011-2012: Hospital-based Influenza Morbidity & Mortality (HIMM) surveillance. J Infect Chemother 2014; 20 (01) 9-14
    CrossrefPubMedGoogle Scholar
  • 39 Guo L, Wei D, Zhang X. et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA Score. Front Microbiol 2019; 10: 2752
    CrossrefPubMedGoogle Scholar
  • 40 Zhou P, Yang X-L, Wang X-G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579 (7798) 270-273
    Google Scholar
  • 41 Pandemic PC-19, Viruses C, Mellitus D. 2 Ranganath Muniyappa and Sriram Gubbi.
  • 42 Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis [Internet]. medRxiv; 2020. Available from: Doi: 10.1101/2020.03.25.20043133
  • 43 Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med 2020; 8 (04) e21 DOI: 10.1016/s2213-2600(20)30116-8.
    CrossrefPubMedGoogle Scholar
  • 44 Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 2019; 4 (20) 131774
    CrossrefPubMedGoogle Scholar
  • 45 Moni MA, Liò P. Network-based analysis of comorbidities risk during an infection: SARS and HIV case studies. BMC Bioinformatics 2014; 15 (01) 333
    CrossrefPubMedGoogle Scholar
  • 46 Naqvi AA, Shah A, Ahmad R, Ahmad N. Developing an integrated treatment pathway for a post-coronary artery bypass grating (CABG) geriatric patient with comorbid hypertension and type 1 diabetes mellitus for treating acute hypoglycemia and electrolyte imbalance. J Pharm Bioallied Sci 2017; 9 (03) 216-220
    CrossrefPubMedGoogle Scholar
  • 47 Murphy TE, McAvay GJ, Allore HG, Stamm JA, Simonelli PF. Contributions of COPD, asthma, and ten comorbid conditions to health care utilization and patient-centered outcomes among US adults with obstructive airway disease. Int J Chron Obstruct Pulmon Dis 2017; 12: 2515-2522
    CrossrefPubMedGoogle Scholar
  • 48 Xu XW, Wu XX, Jiang XG. et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606
    CrossrefPubMedGoogle Scholar
  • 49 Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al; Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Electronic address:, https://www.lancovid.org. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020;34:101623
  • 50 Alraddadi BM, Watson JT, Almarashi A. et al. Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 2016; 22 (01) 49-55
    CrossrefPubMedGoogle Scholar
  • 51 Placzek HE, Madoff LC. Association of age and comorbidity on 2009 influenza A pandemic H1N1-related intensive care unit stay in Massachusetts. Am J Public Health 2014; 104 (11) e118-e125
    CrossrefPubMedGoogle Scholar
  • 52 Gutiérrez-González E, Cantero-Escribano JM, Redondo-Bravo L, San Juan-Sanz I, Robustillo-Rodela A, Cendejas-Bueno E. Influenza Working Group. Effect of vaccination, comorbidities and age on mortality and severe disease associated with influenza during the season 2016-2017 in a Spanish tertiary hospital. J Infect Public Health 2019; 12 (04) 486-491
    CrossrefPubMedGoogle Scholar
  • 53 Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R. et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect 2019; 147: e35
    CrossrefPubMedGoogle Scholar
  • 54 Matsuyama R, Nishiura H, Kutsuna S, Hayakawa K, Ohmagari N. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Public Health 2016; 16 (01) 1203
    CrossrefPubMedGoogle Scholar
  • 55 Alexander DJ, Brown IH. History of highly pathogenic avian influenza. Rev Sci Tech 2009; 28 (01) 19-38
    CrossrefPubMedGoogle Scholar
  • 56 Ito T, Goto H, Yamamoto E. et al. Generation of a highly pathogenic avian influenza A virus from an avirulent field isolate by passaging in chickens. J Virol 2001; 75 (09) 4439-4443
    CrossrefPubMedGoogle Scholar
  • 57 Garbati MA, Fagbo SF, Fang VJ. et al. A comparative study of clinical presentation and risk factors for adverse outcome in patients hospitalised with acute respiratory disease due to MERS coronavirus or other causes. PLoS One 2016; 11 (11) e0165978
    CrossrefPubMedGoogle Scholar
  • 58 Patel U, Malik P, Usman MS, et al. Age-adjusted risk factors associated with mortality and mechanical ventilation utilization amongst COVID-19 hospitalizations--a systematic review and meta-analysis. SN Compr Clin Med 2020;1-10. doi:10.1007/s42399-020-00476-w
  • 59 Booth CM, Matukas LM, Tomlinson GA. et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289 (21) 2801-2809
    CrossrefPubMedGoogle Scholar
  • 60 Shiley KT, Nadolski G, Mickus T, Fishman NO, Lautenbach E. Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. Infect Control Hosp Epidemiol 2010; 31 (07) 676-682
    CrossrefPubMedGoogle Scholar
  • 61 Rahman A, Sarkar A. Risk Factors for Fatal Middle East Respiratory Syndrome Coronavirus Infections in Saudi Arabia: Analysis of the WHO Line List, 2013-2018. Am J Public Health 2019; 109 (09) 1288-1293
    CrossrefPubMedGoogle Scholar
  • 62 Rivers CM, Majumder MS, Lofgren ET. Risks of death and severe disease in patients with Middle East respiratory syndrome coronavirus, 2012-2015. Am J Epidemiol 2016; 184 (06) 460-464
    CrossrefPubMedGoogle Scholar
  • 63 Mauskopf J, Klesse M, Lee S, Herrera-Taracena G. The burden of influenza complications in different high-risk groups: a targeted literature review. J Med Econ 2013; 16 (02) 264-277
    CrossrefPubMedGoogle Scholar